AstraZeneca gets European regulatory nod for oral diabetes treatment


AstraZeneca said European regulators had offered a positive opinion for the oral use of its treatment for type-one diabetes.

The Committee for Medicinal Products for Human Use of the European Medicines Agency had also recommended a new indication for the marketing authorisation of the treatment, Forxiga. Forxiga was the first oral medicine to receive a positive recommendation from the EMA for use in type-one diabetes as an adjunct to insulin, when insulin alone did not provide adequate glycaemic control.

'People with type-one diabetes have not seen oral treatment innovation in decades and we believe today's announcement signals an important advancement for them, as well as a broader understanding of the well-established clinical profile of Forxiga for people living with metabolic diseases,' head of cardiovascular, renal and metabolism Elisabeth Bjork said.

At 1:59pm: (LON:AZN) AstraZeneca PLC share price was +33.5p at 5565.5p

Related content

Ranking the FTSE 100 on its commitment to ESG


A lot of companies talk a good game when it comes to sustainability and climate change, but how many of them actually do what they say they’re going...

Thu, 23/01/2020 - 00:00

What does a high share price mean?


A lot of investors presume that a stock priced at £10 is much more expensive than something priced at 250p. Yes, you need more money to...

Thu, 23/01/2020 - 00:00

Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC

Liberum Capital today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8810p (from 8300p).

Broker Forecasts data provided...

Wed, 22/01/2020 - 08:00

AstraZeneca cancer treatment gets orphan drug designation in US

AstraZeneca said its liver cancer treatment had received orphan drug designation from the US Food and Drug Administration.

Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody...

Mon, 20/01/2020 - 07:27

Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLC

Credit Suisse today reaffirms its outperform investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8500p (from 8200p).

Broker Forecasts data provided...

Thu, 16/01/2020 - 09:20